vTv Therapeutics Presents Data Highlighting Further Potential of TTP273 at American Diabetes Association 77th Scientific Sess...
June 11 2017 - 4:00PM
Business Wire
Lower doses of TTP273 may demonstrate a more
pronounced reduction in HbA1c and other key endpoints
vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that
results from a Phase 2 clinical study of TTP273, an
investigational, oral small molecule GLP-1 receptor (GLP-1R)
agonist for the treatment of Type 2 diabetes, were presented at
the American Diabetes Association 77th Scientific
Sessions.
In a poster presentation titled, “Is Less More? Learning to dose
the oral, non-peptide GLP-1R Agonist, TTP273 in Type 2 Diabetics,”
researchers from vTv reviewed results from a concentration/effect
analysis on the LOGRA study showing that lower doses of TTP273 may
show more pronounced effects for key efficacy endpoints, including
a reduction in HbA1c, weight and fasting plasma glucose. The
characteristics of TTP273 (functionally biased and neuro-endocrine
signaling) provide a potential scientific rationale supporting the
concept that for TTP273, less may be more.
“Further analysis of the Phase 2 data has highlighted a trend
where a lower dose shows more pronounced effects,” said Steve
Holcombe, president and chief executive officer of vTv
Therapeutics. “While additional clinical investigation is needed to
confirm the optimal dose for TTP273, we are enthusiastic about
TTP273’s potential to meaningfully expand the treatment options for
patients with Type 2 diabetes.”
TTP273-201 is a 12-week, multi-center Phase 2, double-blind,
placebo-controlled randomized study of 174 patients with Type 2
diabetes on stable doses of metformin who were randomized to either
placebo or TTP273 (150 mg once (QPM) or twice (BID) daily).
Baseline characteristics were well balanced amongst groups with an
overall mean age of 56 years, mean HbA1c of 8.6% and mean BMI of 32
kg/m2. TTP273 was well tolerated with no severe hypoglycemia
adverse events (AEs). The most common TEAE was diarrhea, mostly
mild in intensity, with only one subject discontinued due to mild
diarrhea (150 mg BID). Less nausea was observed in active groups
than placebo and the only incidence of vomiting occurred with
placebo dosing. Once daily dosing of TTP273 demonstrated
placebo-subtracted decrease from baseline of 0.9% in HbA1c and 0.9
kg in weight.
A copy of the presentation will be made available in
the News & Events section of the Company’s website
following the presentation.
About TTP273
TTP273 is an oral small molecule that works by activating the
GLP-1 receptor. Activation of the GLP-1 receptor leads to the
enhancement of insulin secretion and suppression of glucagon
production and decreased food intake.
There are currently several marketed injectable GLP-1 therapies.
These agents have demonstrated notable glucose lowering in addition
to weight loss; however, their widespread use may be hindered by
the route of administration (injection) and by the high incidence
of gastrointestinal side effects (nausea and vomiting).
About Type 2 Diabetes
Type 2 diabetes is a result of the body’s inability to use
insulin properly to control sugar in the bloodstream. Type 2
diabetes represents up to 95% of diabetes patients, imposing a
growing burden on healthcare systems globally. Diabetes remains the
7th leading cause of death in the United States, costing the
healthcare system $245 billion annually. According to
the American Diabetes Association, there are 29.1 million
Americans, or 9.3% of the population, living with diabetes.
About vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical
company engaged in the discovery and development of orally
administered small molecule drug candidates to fill significant
unmet medical needs. vTv has a pipeline of clinical drug candidates
led by programs for the treatment of Alzheimer’s disease and Type 2
diabetes as well as treatment of inflammatory disorders and the
prevention of muscle weakness. Last month, vTv announced positive
topline results from a placebo and active-comparator-controlled
Phase 2b clinical study of TTP399, a liver-selective glucokinase
activator (GKA) under development for the treatment of Type 2
diabetes.
The Company’s drug candidates were discovered with its
high-throughput drug discovery platform, TTP Translational
Technology®, which translates the functional modulation of human
proteins into safe and effective medicines. For further company
information, visit www.vtvtherapeutics.com.
Forward-Looking Statements
This release contains forward-looking statements, which involve
risks and uncertainties. These forward-looking statements can be
identified by the use of forward-looking terminology, including the
terms “anticipate,” “believe,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and, in each case, their
negative or other various or comparable terminology. All statements
other than statements of historical facts contained in this
release, including statements regarding the timing of our clinical
trials, our strategy, future operations, future financial position,
future revenue, projected costs, prospects, plans, objectives of
management and expected market growth are forward-looking
statements. These statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Important factors that
could cause our results to vary from expectations include those
described under the heading “Risk Factors” in our Annual Report on
Form 10-K and our other filings with the SEC. These forward-looking
statements reflect our views with respect to future events as of
the date of this release and are based on assumptions and subject
to risks and uncertainties. Given these uncertainties, you should
not place undue reliance on these forward-looking statements. These
forward-looking statements represent our estimates and assumptions
only as of the date of this release and, except as required by law,
we undertake no obligation to update or review publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise after the date of this release. We
anticipate that subsequent events and developments will cause our
views to change. Our forward-looking statements do not reflect the
potential impact of any future acquisitions, merger, dispositions,
joint ventures or investments we may undertake. We qualify all of
our forward-looking statements by these cautionary statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170611005037/en/
vTv Therapeutics Inc.InvestorsMichael Gibralter,
646-378-2938IR@vtvtherapeutics.comorMediaPure Communications
Inc.Katie Engleman, 910-509-3977Katie@purecommunications.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Aug 2024 to Sep 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Sep 2023 to Sep 2024